论文部分内容阅读
目的调查急性髓系白血病患者DA方案首次化疗后临床血小板输注情况及输血不良反应的发生率。方法收集病例的输血记录、输血科发血记录、患者住院病历输血不良反应记录、输血种类及输血量等,利用SPSS对相关数据进行分析处理。结果 184例患者共输注血小板668次;输注前血小板为(11.8±10.0)×109/L,输注后血小板(24.4±23.9)×109/L,患者血小板输注后较输注前计数显著上升(Z=15.975,P<0.05)。有26例出现不同程度出血,出血发生率为14.1%。血小板申请平均等待时间为1.5 d,严重出血病例没有发现因血小板输注延误造成。共出现24次输血不良反应,发生率为3.6%,其中发热非溶血性输血反应10例,过敏反应14例。结论血小板输注是急性髓系白血病化疗患者重要的支持治疗,应严格掌握输注指征,综合评价患者出血状况等临床因素,从而提高输注有效率,减少输血不良反应。
Objective To investigate the clinical platelet transfusion and the incidence of adverse transfusion reactions after first chemotherapy in patients with acute myeloid leukemia. Methods The blood transfusion records, blood transfusion records, transfusion records of transfusion patients, blood transfusion and blood transfusion were collected and analyzed by SPSS. Results A total of 184 patients received 668 platelet transfusions; the number of platelets before transfusion was (11.8 ± 10.0) × 109 / L and after transfusion (24.4 ± 23.9) × 109 / L, Significantly increased (Z = 15.975, P <0.05). There are 26 cases of varying degrees of bleeding, the incidence of bleeding was 14.1%. The average waiting time for platelet application was 1.5 days. Serious bleeding was not found due to delayed platelet transfusion. A total of 24 adverse transfusion reactions occurred in 3.6% of them, including 10 cases of fever and non-hemolytic transfusion reactions and 14 cases of allergic reactions. Conclusion Platelet transfusion is an important supportive treatment for patients with acute myeloid leukemia chemotherapy. The indications of infusion should be strictly controlled and the clinical factors such as bleeding status should be evaluated comprehensively to improve the efficiency of infusion and reduce the adverse reactions of transfusion.